Belite Bio wins FDA Priority Review for tinlarebant in Stargardt disease NDA

Reuters2026/08/11 20:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Belite Bio mendapat penerimaan FDA untuk NDA tinlarebant bagi Stargardt Disease Type 1, disertai Priority Review.
Tenggat keputusan PDUFA ditetapkan 12 Februari 2027; jika disetujui, tinlarebant berpotensi menjadi terapi pertama untuk STGD1.
Pengajuan didukung uji fase 3 DRAGON, menunjukkan penurunan 35,7% laju pertumbuhan lesi atrofi retina versus plasebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608111601PRIMZONEFULLFEED9807987) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Belite Bio wins FDA Priority Review for tinlarebant in Stargardt disease NDA

You may also like

Crypto prices